A rapid and reliable test for BRCA1 and BRCA2 founder mutation analysis in paraffin tissue using pyrosequencing

Journal of Molecular Diagnostics

Volumn 11, Issue 3, 2009, Pages 176-181

  Zhang, Liying ^a   Kirchhoff, Tomas ^a   Yee, Cindy J ^a,b   Offit, Kenneth ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^b MEMORIAL HEALTH UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BRCA1 PROTEIN; BRCA2 PROTEIN; PARAFFIN;

ACCURACY; ARTICLE; BLOOD ANALYSIS; CLINICAL RESEARCH; CONTROLLED STUDY; DNA ISOLATION; FALSE NEGATIVE RESULT; FRAMESHIFT MUTATION; GENE MUTATION; GENETIC ANALYSIS; HUMAN; LABORATORY DIAGNOSIS; MUTATIONAL ANALYSIS; NON INVASIVE MEASUREMENT; PYROSEQUENCING; SALIVA ANALYSIS; ECONOMICS; FOUNDER EFFECT; GENETICS; METHODOLOGY; MOLECULAR GENETICS; NUCLEOTIDE SEQUENCE; REPRODUCIBILITY; TIME;

BASE SEQUENCE; BRCA1 PROTEIN; BRCA2 PROTEIN; DNA MUTATIONAL ANALYSIS; FOUNDER EFFECT; HUMANS; MOLECULAR SEQUENCE DATA; PARAFFIN EMBEDDING; REPRODUCIBILITY OF RESULTS; TIME FACTORS;

EID: 67149099839     PISSN: 15251578     EISSN: None     Source Type: Journal    
DOI: 10.2353/jmoldx.2009.080137     Document Type: Article

References (28)

1. Ford D, Easton DF, Stratton M, Narod S, Goldgar D, Devilee P, Bishop DT, Weber B, Lenoir G, Chang-Claude J, Sobol H, Teare MD, Struewing J, Arason A, Scherneck S, Peto J, Rebbeck TR, Tonin P, Neuhausen S, Barkardottir R, Eyfjord J, Lynch H, Ponder BA, Gayther SA, Zelada-Hedman M: Genetic heterogeneity and penetrance analysis of the BRCA1 and BRCA2 genes in breast cancer families. The Breast Cancer Linkage Consortium. Am J Hum Genet 1998, 62:676-689
2. Satagopan JM, Offit K, Foulkes W, Robson ME, Wacholder S, Eng CM, Karp SE, Begg CB: The lifetime risks of breast cancer in Ashkenazi Jewish carriers of BRCA1 and BRCA2 mutations. Cancer Epidemiol Biomarkers Prev 2001, 10:467-473
3. Struewing JP, Hartge P, Wacholder S, Baker SM, Berlin M, McAdams M, Timmerman MM, Brody LC, Tucker MA: The risk of cancer associated with specific mutations of BRCA1 and BRCA2 among Ashkenazi Jews. N Engl J Med 1997, 336:1401-1408
4. Oddoux C, Struewing JP, Clayton CM, Neuhausen S, Brody LC, Kaback M, Haas B, Norton L, Borgen P, Jhanwar S, Goldgar D, Ostrer H, Offit K: The carrier frequency of the BRCA2 6174delT mutation among Ashkenazi Jewish individuals is approximately 1%. Nat Genet 1996, 14:188-190
5. Tonin P, Weber B, Offit K, Couch F, Rebbeck TR, Neuhausen S, Godwin AK, Daly M, Wagner-Costalos J, Berman D, Grana G, Fox E, Kane MF, Kolodner RD, Krainer M, Haber DA, Struewing JP, Warner E, Rosen B, Lerman C, Peshkin B, Norton L, Serova O, Foulkes WD, Lynch HT, Lenior GM, Narod SA, Garber JE: Frequency of recurrent BRCA1 and BRCA2 mutations in Ashkenazi Jewish breast cancer families. Nat Med 1996, 2:1179-1183
6. Robson M, Offit K: Clinical practice. Management of an inherited predisposition to breast cancer. N Engl J Med 2007, 357:154-162
7. Kauff ND, Perez-Segura P, Robson ME, Scheuer L, Siegel B, Schluger A, Rapaport B, Frank TS, Nafa K, Ellis NA, Parmigiani G, Offit K: Incidence of non-founder BRCA1 and BRCA2 mutations in high risk Ashkenazi breast and ovarian cancer families. J Med Genet 2002, 39:611-614
8. Narod SA, Offit K: Prevention and management of hereditary breast cancer. J Clin Oncol 2005, 23:1656-1663
9. Bernstein JL, Thompson WD, Casey G, DiCioccio RA, Whittemore AS, Diep AT, Thakore SS, Vaziri S, Xue S, Haile RW: Comparison of techniques for the successful detection of BRCA1 mutations in fixed paraffin-embedded tissue. Cancer Epidemiol Biomarkers Prev 2002, 11:809-814
10. th Annual Meeting, 1999, Abstract A58
11. Adank MA, Brogi E, Bogomolniy F, Wadsworth EA, Lafaro KJ, Yee CJ, Kirchhoff T, Meijers-Heijboer EJ, Kauff ND, Boyd J, Offit K: Accuracy of BRCA1 and BRCA2 founder mutation analysis in formalin-fixed and paraffin-embedded (FFPE) tissue. Fam Cancer 2006, 5:337-342
12. Kuperstein G, Foulkes WD, Ghadirian P, Hakimi J, Narod SA: A rapid fluorescent multiplexed-PCR analysis (FMPA) for founder mutations in the BRCA1 and BRCA2 genes. Clin Genet 2000, 57:213-220
13. Fakhrai-Rad H, Pourmand N, Ronaghi M: Pyrosequencing: an accurate detection platform for single nucleotide polymorphisms. Hum Mutat 2002, 19:479-485
14. Ronaghi M: Pyrosequencing sheds light on DNA sequencing. Genome Res 2001, 11:3-11
15. Chen DC, Saarela J, Nuotio I, Jokiaho A, Peltonen L, Palotie A: Comparison of GenFlex tag array and pyrosequencing in SNP genotyping. J Mol Diagn 2003, 5:243-249
16. Jordan JA, Butchko AR, Durso MB: Use of pyrosequencing of 16S rRNA fragments to differentiate between bacteria responsible for neonatal sepsis. J Mol Diagn 2005, 7:105-110
17. Ahmadian A, Lundeberg J, Nyren P, Uhlen M, Ronaghi M: Analysis of the p53 tumor suppressor gene by pyrosequencing. Biotechniques 2000, 28:140-147
18. Garcia CA, Ahmadian A, Gharizadeh B, Lundeberg J, Ronaghi M, Nyren P: Mutation detection by pyrosequencing: sequencing of exons 5-8 of the p53 tumor suppressor gene. Gene 2000, 253:249-257
19. Colella S, Shen L, Baggerly KA, Issa JP, Krahe R: Sensitive and quantitative universal pyrosequencing methylation analysis of CpG sites. Biotechniques 2003, 35:146-150
20. Tost J, Dunker J, Gut IG: Analysis and quantification of multiple methylation variable positions in CpG islands by pyrosequencing. Biotechniques 2003, 35:152-156
21. Uhlmann K, Brinckmann A, Toliat MR, Ritter H, Nurnberg P: Evaluation of a potential epigenetic biomarker by quantitative methyl-single nucleotide polymorphism analysis. Electrophoresis 2002, 23:4072-4079
22. Ogino S, Kawasaki T, Brahmandam M, Yan L, Cantor M, Namgyal C, Mino-Kenudson M, Lauwers GY, Loda M, Fuchs CS: Sensitive sequencing method for KRAS mutation detection by pyrosequencing. J Mol Diagn 2005, 7:413-421
23. Nosho K, Kawasaki T, Ohnishi M, Suemoto Y, Kirkner GJ, Zepf D, Yan L, Longtine JA, Fuchs CS, Ogino S: PIK3CA mutation in colorectal cancer: relationship with genetic and epigenetic alterations. Neoplasia 2008, 10:534-541
24. Spittle C, Ward MR, Nathanson KL, Gimotty PA, Rappaport E, Brose MS, Medina A, Letrero R, Herlyn M, Edwards RH: Application of a BRAF pyrosequencing assay for mutation detection and copy number analysis in malignant melanoma. J Mol Diagn 2007, 9:464-471
25. Akbari M, Hansen MD, Halgunset J, Skorpen F, Krokan HE: Low copy number DNA template can render polymerase chain reaction error prone in a sequence-dependent manner. J Mol Diagn 2005, 7:36-39
26. Quach N, Goodman MF, Shibata D: In vitro mutation artifacts after formalin fixation and error prone translesion synthesis during PCR. BMC Clin Pathol 2004, 4:1
27. Williams C, Ponten F, Moberg C, Soderkvist P, Uhlen M, Ponten J, Sitbon G, Lundeberg J: A high frequency of sequence alterations is due to formalin fixation of archival specimens. Am J Pathol 1999, 155:1467-1471
28. Wong C, DiCioccio RA, Allen HJ, Werness BA, Piver MS: Mutations in BRCA1 from fixed, paraffin-embedded tissue can be artifacts of preservation. Cancer Genet Cytogenet 1998, 107:21-27